These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2873 related items for PubMed ID: 15589385

  • 21. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [Abstract] [Full Text] [Related]

  • 22. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ.
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [Abstract] [Full Text] [Related]

  • 23. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
    Arnold LM, Hudson JI, Wang F, Wohlreich MM, Prakash A, Kajdasz DK, Chappell AS.
    Clin J Pain; 2009 Aug; 25(6):461-8. PubMed ID: 19542792
    [Abstract] [Full Text] [Related]

  • 24. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
    Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ.
    J Psychiatr Res; 2007 Aug; 41(3-4):311-8. PubMed ID: 16934840
    [Abstract] [Full Text] [Related]

  • 25. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S, Desaiah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD.
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [Abstract] [Full Text] [Related]

  • 27. Paroxetine versus placebo: a double-blind comparison in depressed patients.
    Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC.
    J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
    [Abstract] [Full Text] [Related]

  • 28. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B.
    Depress Anxiety; 2007 Dec; 24(1):1-14. PubMed ID: 16894619
    [Abstract] [Full Text] [Related]

  • 29. Duloxetine in treatment of anxiety symptoms associated with depression.
    Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ.
    Depress Anxiety; 2003 Dec; 18(2):53-61. PubMed ID: 12964171
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 31. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
    Anghelescu IG, Kohnen R, Szegedi A, Klement S, Kieser M.
    Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
    [Abstract] [Full Text] [Related]

  • 32. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
    Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Tylee A.
    Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
    [Abstract] [Full Text] [Related]

  • 33. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
    Arnold LM, Meyers AL, Sunderajan P, Montano CB, Kass E, Trivedi M, Wohlreich MM.
    Ann Clin Psychiatry; 2008 May; 20(4):187-93. PubMed ID: 19034749
    [Abstract] [Full Text] [Related]

  • 34. History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.
    Pae CU, Masand PS, Marks DM, Krulewicz S, Han C, Peindl K, Mannelli P, Patkar AA.
    World J Biol Psychiatry; 2009 May; 10(4 Pt 2):435-41. PubMed ID: 19382010
    [Abstract] [Full Text] [Related]

  • 35. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
    Pae CU, Kim YJ, Won WY, Kim HJ, Lee S, Lee CU, Lee SJ, Kim DW, Lee C, Min WS, Kim CC, Paik IH, Serretti A.
    Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
    [Abstract] [Full Text] [Related]

  • 36. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
    Kasper S, Volz HP, Möller HJ, Dienel A, Kieser M.
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
    [Abstract] [Full Text] [Related]

  • 37. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [Abstract] [Full Text] [Related]

  • 38. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA.
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [Abstract] [Full Text] [Related]

  • 39. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF.
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [Abstract] [Full Text] [Related]

  • 40. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME.
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 144.